drugset / Trial / NCT04392141

Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

NCT04392141

Phase 1/2 Completed 120 enrolled Kermanshah University of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate, or severe pneumonia (according to the NIH guideline) were treated with conventional treatment regimens (controls) as well as in combination with oral administration of colchicine plus herbal phenolic monoterpene fractions (intervention arm). After randomization, each group received the mentioned treatments and were evaluated for different variables including mortality, hospitalization duration, intensive care unit (ICU) administration ratios as well as laboratory variables such as leukocytes and lymphocytes count. The follow-up period considered as 2 weeks after discharge. The mentioned variables were assessed as before and after receiving the treatment in each group as well as intergroup analysis for comparing both baseline and final values.

Timeline

Start
2020-04-01
Primary completion
2020-11-01
Completion
2020-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule Oral
Subject Herbal Phenolic Monoterpene Fractions Unknown Oral

Indications